RESUMEN
ABSTRACT: We report the case of a 25-year-old man who was undergoing follow-up for neurofibromatosis type 1. The man underwent 68 Ga-DOTATOC PET/CT for a suspected well-differentiated duodenal neuroendocrine tumor. This examination did not reveal any significant uptake, whereas complementary 18 F-FDG PET/CT showed moderate 18 F-FDG uptake in the primary tumor as well as the adenopathy. Histology, a well-differentiated duodenal neuroendocrine tumor was confirmed, consistent with the diagnosis of somatostatinoma. Although rare, this well-differentiated neuroendocrine tumor should be kept in mind as a possible source of false-negative somatostatin receptor PET/CT findings.
Asunto(s)
Octreótido , Compuestos Organometálicos , Tomografía Computarizada por Tomografía de Emisión de Positrones , Somatostatinoma , Humanos , Masculino , Adulto , Octreótido/análogos & derivados , Somatostatinoma/diagnóstico por imagen , Reacciones Falso Negativas , Tumores Neuroendocrinos/diagnóstico por imagen , Tumores Neuroendocrinos/patologíaRESUMEN
A 52-year-old woman underwent esophagogastroduodenoscopy after an abnormal medical examination, which revealed a mass lesion over half the circumference of the superior duodenal angulus. Immunostaining was diffusely positive for somatostatin, synaptophysin, and chromogranin A. A 3 cm-sized mass in the pancreaticoduodenal region and multiple nodular lesions of a few mm in both lobes of the liver were revealed by CT. The diagnosis is primary somatostatin-producing tumor of the duodenum with multiple liver metastases. She underwent gastric jejunal bypass for impaired transit. Afterwards hepatic infusion and systemic chemotherapy were continued, and 5 years passed without progression. When she stopped chemotherapy for 6 months, she started somatostatin analogue therapy because of the increase of the tumors. The tumors did not increase, and 20 years have passed since the start of treatment. We report a case of primary somatostatin-producing tumor of the duodenum with liver metastases that is still alive for a long period of time, with a review of the literature.
Asunto(s)
Neoplasias Duodenales , Neoplasias Hepáticas , Somatostatina , Somatostatinoma , Femenino , Humanos , Persona de Mediana Edad , Neoplasias Duodenales/tratamiento farmacológico , Neoplasias Duodenales/patología , Neoplasias Duodenales/cirugía , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/secundario , Somatostatina/análogos & derivados , Somatostatina/análisis , Somatostatina/uso terapéutico , Somatostatinoma/tratamiento farmacológico , Somatostatinoma/secundario , Somatostatinoma/cirugía , Resultado del TratamientoRESUMEN
BACKGROUND AND AIMS: Somatostatinoma of the ampulla of Vater (SAV) is a rare neuroendocrine tumor that usually appears with atypical clinical manifestations and is associated with Von Recklinghausen's disease. The aims of this study were to systematically review the literature regarding SAV and to highlight the clinicopathological characteristics and optimal therapeutic management of this rare entity. METHODS: A systematic search of the literature in PubMed/Medline and Scopus databases was performed by two independent investigators, including all case reports and case series concerning SAVs from 1980 until September 2021. RESULTS: In total, 37 articles were retrieved, including 43 patients, with a male to female ratio of 1.8:1 and a mean age of 46.8 ± 11.3 years (mean, SD). For 23 out of 43 patients (53.5%), Von Recklinghausen's disease was proved. The main clinical manifestations were abdominal pain (41.9%), jaundice (27.9%), weight loss (20.9%) and bowel disorders (20.9%). Typical histological findings included psammoma bodies, nests or clusters of epithelial cells with eosinophilic cytoplasm, while somatostatin staining was positive in 35 patients (81.4%), chromogranin-A in 21 patients (48.8%) and synaptophysin in 18 patients (41.9%). Surgery was the initial therapeutic approach in 34 patients (79.1%), whereas Whipple's procedure was the preferred surgical approach in 23 patients (53.4%). The longest survival among included patients was 13 years and only two postoperative deaths (4.7%) were reported. CONCLUSIONS: Somatostatinomas of the ampulla of Vater are rare malignancies that require increased physicians' suspicion and accurate surgical approach in order to achieve optimal therapeutic results.
Asunto(s)
Ampolla Hepatopancreática , Neoplasias Duodenales , Neurofibromatosis 1 , Neoplasias Pancreáticas , Somatostatinoma , Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Somatostatinoma/complicaciones , Somatostatinoma/patología , Somatostatinoma/cirugía , Neurofibromatosis 1/complicaciones , Neurofibromatosis 1/patología , Neurofibromatosis 1/cirugía , Ampolla Hepatopancreática/patología , Neoplasias Duodenales/patología , Neoplasias Pancreáticas/patologíaRESUMEN
OBJECTIVES: Functional neuroendocrine tumors (FNETs) are characterized by excess secretion of disease-specific hormones. In this study, we attempted to define survival trends in patients with some of these uncommon tumors. METHODS: Using the Surveillance, Epidemiology, and End Results database, 529 patients with FNETs (gastrinoma, insulinoma, glucagonoma, VIPoma, and somatostatinoma) were identified. We analyzed patient and tumor characteristics, overall survival, and cancer-specific survival. RESULTS: Functional neuroendocrine tumors were found to be more predominant in White patients older than 50 years. Most common FNETs were gastrinoma (56.3%) and insulinoma (23.8%). Most FNETs were found in the pancreas, with the second most common location being the small bowel. Surgery was the primary modality of treatment, used in 55.8% of the cases. Median overall survival was 9.8 years (95% confidence interval [CI], 7.9-11.8) with a median cancer-specific survival of 18.5 years (95% CI, 12.8-24.2). In multivariate analysis, age >50 years (hazard ratio [HR], 2.7; 95% CI, 2.02-3.64), no surgical resection (HR, 1.88; 95% CI, 1.43-2.46), metastasis (HR, 3.0; 95% CI, 2.0-4.5), and poor differentiation were associated with poor survival. Site and histology did not have a significant impact on survival (P = 0.82 and 0.57 respectively). CONCLUSIONS: Our study highlights the most important prognostic factors for gastrointestinal FNETs.
Asunto(s)
Gastrinoma , Insulinoma , Tumores Neuroendocrinos , Neoplasias Pancreáticas , Somatostatinoma , Humanos , Persona de Mediana Edad , Tumores Neuroendocrinos/cirugía , Tumores Neuroendocrinos/patología , Insulinoma/patología , Neoplasias Pancreáticas/cirugíaRESUMEN
ABSTRACT: We report a father and his daughter who both had multiple somatostatinomas in the duodenal bulb without a known syndrome. The father, at age 68 years, was incidentally found to harbor 4 approximately 1.5-cm well-differentiated neuroendocrine tumors in the duodenal bulb. His preoperative somatostatin level was elevated. He underwent partial duodenectomy and regional lymph node dissection; one lymph node was positive for metastasis. One year postoperatively, a recurrence was found in the surgical bed; he was treated with octreotide for 2 years, which stabilized the recurrent tumor. Ten years postoperatively, the mucosa of his remaining duodenum was normal. His daughter, at age 53 years, was found to harbor multiple small neuroendocrine tumors in the duodenal bulb. Immunostaining of available specimens showed that the neuroendocrine tumors from the father and daughter both were strongly positive for somatostatin. Micronodules of somatostatin-expressing neuroendocrine cells were found in the parts of the specimens uninvolved with the tumors. Both patients exhibited no evidence of known syndromes associated with somatostatinoma. The daughter did not harbor mutations in 93 genes commonly found in genetic tumor syndromes. The 2 cases thus suggest a novel, autosomal dominant, genetic syndrome of familial duodenal somatostatinomatosis.
Asunto(s)
Neoplasias Duodenales , Tumores Neuroendocrinos , Neoplasias Pancreáticas , Somatostatinoma , Masculino , Humanos , Anciano , Persona de Mediana Edad , Neoplasias Duodenales/genética , Neoplasias Duodenales/complicaciones , Recurrencia Local de Neoplasia , Duodeno/patología , Somatostatinoma/diagnóstico , Somatostatinoma/genética , Somatostatinoma/complicaciones , Tumores Neuroendocrinos/patología , Somatostatina/uso terapéutico , Neoplasias Pancreáticas/patologíaAsunto(s)
Neoplasias Duodenales , Tumores Neuroendocrinos , Neurofibromatosis 1 , Neoplasias Pancreáticas , Somatostatinoma , Neoplasias Duodenales/diagnóstico por imagen , Humanos , Tumores Neuroendocrinos/diagnóstico por imagen , Tumores Neuroendocrinos/cirugía , Neoplasias Pancreáticas/diagnóstico por imagen , Neoplasias Pancreáticas/cirugía , Somatostatinoma/diagnóstico por imagenRESUMEN
BACKGROUND/AIM: Somatostatinomas (SSomas) constitute a rare neuroendocrine tumor. The purpose of this study was to evaluate the current published literature about pancreatic SSomas and report epidemiologic and clinicopathologic data for this entity. PATIENTS AND METHODS: A combined automated and manual systematic database search of the literature was performed using electronic search engines (Medline PubMed, Scopus, Ovid and Cochrane Library), until February 2020. Statistical analysis was performed using the R language and environment for statistical computing. RESULTS: Overall, the research revealed a total of 36 pancreatic SSoma cases. Patient mean age was 50.25 years. The most common pancreatic location was the pancreatic head (61.8%). The most frequent clinical symptom was abdominal pain (61.1%). Diagnostic algorithm most often included Computed Tomography and biopsy; surgical resection was performed in 28 cases. Out of the 36 cases, 22 had been diagnosed with a metastatic tumor and metastasectomy was performed in 6 patients with a worse overall survival (OS) (p=0.029). In total, OS was 47.74 months. CONCLUSION: Patients with metastatic disease did not benefit from metastasectomy, but the sample size was small to reach definite conclusions. However, further studies with longer follow-up are needed for a better evaluation of these results.
Asunto(s)
Metastasectomía , Tumores Neuroendocrinos , Neoplasias Pancreáticas , Somatostatinoma , Humanos , Persona de Mediana Edad , Neoplasias Pancreáticas/terapia , Tomografía Computarizada por Rayos XRESUMEN
Pancreatic neuroendocrine tumors (pNETs) occur due to the abnormal growth of pancreatic islet cells and predominantly develop in the duodenal-pancreatic region. Somatostatinoma is one of the pNETs associated with tumors of pancreatic δ cells, which produce and secrete somatostatin. Limited information is currently available on the pathogenic mechanisms of somatostatinoma. The large-conductance Ca2+-activated K+ (BKCa) channel is expressed in several types of cancer cells and regulates cell proliferation, migration, invasion, and metastasis. In the present study, the functional expression of the BKCa channel was examined in a human somatostatinoma QGP-1 cell line. In QGP-1 cells, outward currents were elicited by membrane depolarization at pCa 6.5 (300 nM) in the pipette solution and inhibited by the specific BKCa channel blocker, paxilline. Paxilline-sensitive currents were detected, even at pCa 8.0 (10 nM) in the pipette solution, in QGP-1 cells. In addition to the α and ß2-4 subunits of the BKCa channel, the novel regulatory γ1 subunit (BKCaγ1) was co-localized with the α subunit in QGP-1 cells. Paxilline-sensitive currents at pCa 8.0 in the pipette solution were reduced by the siRNA knockdown of BKCaγ1. Store-operated Ca2+ entry was smaller in BKCaγ1 siRNA-treated QGP-1 cells. The proliferation of QGP-1 cells was attenuated by paxilline or the siRNA knockdown of BKCaγ1. These results strongly suggest that BKCaγ1 facilitates the proliferation of human somatostatinoma cells. Therefore, BKCaγ1 may be a novel therapeutic target for somatostatinoma.
Asunto(s)
Calcio/metabolismo , Canales de Potasio de Gran Conductancia Activados por el Calcio/metabolismo , Neoplasias Pancreáticas/metabolismo , Somatostatinoma/metabolismo , Línea Celular Tumoral , Proliferación Celular/genética , Técnicas de Silenciamiento del Gen , Humanos , Inmunohistoquímica , Indoles/farmacología , Canales de Potasio de Gran Conductancia Activados por el Calcio/genética , Neoplasias Pancreáticas/genética , Bloqueadores de los Canales de Potasio/farmacología , ARN Interferente Pequeño , Somatostatinoma/genéticaRESUMEN
Background: Peptide receptor radionuclide therapy (PRRT) is a validated treatment for somatostatin receptor overexpressing neuroendocrine tumors (NETs). The NETTER-1 trial demonstrated a pronounced positive effect on progression-free-survival compared to high dose somatostatin analogs (SSAs), with a strong tendency toward overall survival benefit. Our aim was to investigate the influence of pretreatment with everolimus and/or sunitinib on subacute hematotoxicity of PRRT. To assess the influence of prior treatment with everolimus/sunitinib might be of clinical relevance due to the link between short-term hematotoxicity and increased incidence of late hematotoxicity.Material and methods: Our single-center retrospective study enrolled all patients treated with 177Lu-DOTATATE PRRT (1-4 cycles of 7.4 GBq), between November 2013 and July 2018. Patients were assigned to two groups according to their pretreatment: no targeted agents (N = 41), or targeted agents (everolimus, sunitinib or both; N = 41). The end point was subacute hematotoxicity, defined as the nadir value between the first administration until 3 months after the last administration, using the CTCAE 4.03 classification. The impact of splenectomy was also explored.Results: Eighty percent of patients had a primary gastroenteropancreatic NET. No statistically significant differences in severe subacute hematotoxicity were seen in the pretreated group vs. the naive group for hemoglobin (grade 3/4: 12% vs. 22%), neither for leucocytes (grade 3/4: 10% vs. 7%), neutrophils (grade 3/4: 5% vs. 7%), lymphocytes (grade 3/4: 49% vs. 37%) and platelets (grade 3/4: 15% vs. 15%). Furthermore, we observed significantly lower toxicity for total white blood cells, lymphocytes and platelets in the subgroup that had splenectomy (N = 12). Limitations of this study include the potential bias in lack of use of targeted agents in patients more susceptible to toxicity, and the limited number of patients and events.Conclusions: In a patient cohort with NET pretreated with everolimus and/or sunitinib, we could not demonstrate a significant effect of prior/pretreatment with everolimus and/or sunitinib on the subacute hematotoxicity of 177Lu-DOTATATE PRRT.
Asunto(s)
Antineoplásicos/uso terapéutico , Everolimus/uso terapéutico , Enfermedades Hematológicas/inducido químicamente , Neoplasias Intestinales/tratamiento farmacológico , Tumores Neuroendocrinos/tratamiento farmacológico , Octreótido/análogos & derivados , Compuestos Organometálicos/efectos adversos , Neoplasias Pancreáticas/tratamiento farmacológico , Radiofármacos/efectos adversos , Somatostatinoma/tratamiento farmacológico , Neoplasias Gástricas/tratamiento farmacológico , Sunitinib/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Anemia/inducido químicamente , Femenino , Humanos , Neoplasias Intestinales/sangre , Leucopenia/inducido químicamente , Linfopenia/inducido químicamente , Masculino , Persona de Mediana Edad , Tumores Neuroendocrinos/sangre , Octreótido/administración & dosificación , Octreótido/efectos adversos , Compuestos Organometálicos/administración & dosificación , Compuestos Organometálicos/farmacocinética , Neoplasias Pancreáticas/sangre , Supervivencia sin Progresión , Radiofármacos/administración & dosificación , Receptores de Somatostatina/metabolismo , Estudios Retrospectivos , Somatostatinoma/sangre , Somatostatinoma/mortalidad , Esplenectomía , Neoplasias Gástricas/sangre , Trombocitopenia/inducido químicamente , Adulto JovenRESUMEN
We report an index case of a male patient who presented with all clinical manifestations of Pacak-Zhuang syndrome, including early-age polycythemia, multiple pheochromocytomas/paragangliomas, duodenal somatostatinoma, and ocular findings. Sequencing analysis detected an EPAS1 mutation in all tumors tested, but not in the germline.
Asunto(s)
Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/genética , Enfermedades Hereditarias del Ojo/genética , Neoplasias Primarias Múltiples/genética , Policitemia/genética , Neoplasias de las Glándulas Suprarrenales/genética , Neoplasias Duodenales/genética , Humanos , Masculino , Mutación , Cuerpos Paraaórticos/patología , Paraganglioma/genética , Feocromocitoma/genética , Somatostatinoma/genética , Síndrome , Adulto JovenRESUMEN
INTRODUCTION: Pancreatic Neuroendocrine Tumours (p-NETs) are an important disease entity and comprise of peptide-secreting tumours often with a functional syndrome. Accounting for a small percentage of all pancreatic tumours, they have a good overall survival rate when diagnosed early, with surgery being curative. The role of nuclear medicine in the diagnosis and treatment of these tumours is evident. However, the vast majority of patients will require extensive imaging in the form of conventional radiological techniques. It is important for clinicians to have a fundamental understanding of the p-NET appearances to aid prompt identification and to help direct management through neoplastic staging. METHODS: This article will review the advantages and disadvantages of conventional radiological techniques in the context of p-NETs and highlight features that these tumours exhibit. CONCLUSION: Pancreatic neuroendocrine tumours are a unique collection of neoplasms that have markedly disparate clinical features but similar imaging characteristics. Most p-NETs are small and welldefined with homogenous enhancement following contrast administration, although larger and less welldifferentiated tumours can demonstrate areas of necrosis and cystic architecture with heterogeneous enhancement characteristics. Prognosis is generally favourable for these tumours with various treatment options available. However, conventional radiological techniques will remain the foundation for the initial diagnosis and staging of these tumours, and a grasp of these modalities is extremely important for physicians.
Asunto(s)
Tumores Neuroendocrinos/diagnóstico por imagen , Neoplasias Pancreáticas/diagnóstico por imagen , Cintigrafía , Radiofármacos , Medios de Contraste , Endoscopía , Gastrinoma/diagnóstico por imagen , Glucagonoma/diagnóstico por imagen , Humanos , Metástasis de la Neoplasia , Estadificación de Neoplasias , Pronóstico , Radiografía , Somatostatinoma/diagnóstico por imagen , Resultado del Tratamiento , Ultrasonografía , Vipoma/diagnóstico por imagenRESUMEN
Somatostatinomas are rare neuroendocrine tumours, mostly located in the pancreas or duodenum, with an estimated incidence of 1 in 40 million. Duodenal somatostatinomas (DSs) are usually found in association with neurofibromatosis type 1 (NF1), tuberous sclerosis and Von Hippel-Lindau syndrome. Gastrointestinal stromal tumours (GIST) have also been described in NF1, but the association with somatostatinoma is very uncommon. We report the case of a patient with NF1 who presented with obstructive jaundice due to multiple firm nodules around the ampulla of Vater. A pancreaticoduodenectomy was performed and revealed a 1 cm duodenal/ampullary mass which stained positive for somatostatin, together with a GIST also found on the duodenal wall. Despite its rarity, ampullary somatostatinomas should be considered in the differential diagnosis of biliary tract dilation in patients with NF1.
Asunto(s)
Tumores del Estroma Gastrointestinal/complicaciones , Ictericia Obstructiva/diagnóstico , Neurofibromatosis 1/complicaciones , Somatostatinoma/patología , Adulto , Cuidados Posteriores , Diagnóstico Diferencial , Neoplasias Duodenales/patología , Neoplasias Duodenales/cirugía , Femenino , Tumores del Estroma Gastrointestinal/patología , Tumores del Estroma Gastrointestinal/cirugía , Humanos , Ictericia Obstructiva/etiología , Ictericia Obstructiva/cirugía , Tumores Neuroendocrinos/epidemiología , Neurofibromatosis 1/diagnóstico , Neoplasias Pancreáticas/patología , Neoplasias Pancreáticas/cirugía , Pancreaticoduodenectomía/métodos , Somatostatina/metabolismo , Somatostatinoma/complicaciones , Somatostatinoma/cirugía , Resultado del TratamientoRESUMEN
Neurofibromatosis type 1 (NF1, von Recklinghausen disease) is inherited in autosomal dominant way genetic disorder, with an incidence at birth 1:3000. It is one of the most common congenital disorders. It is characterized by café-au-lait spots, neurofibromas, and less common MPTST and gliomas of the optic nerve. It is caused by germline mutations of the NF1 gene, which acts as tumor suppressor. Inactivation of the gene leads to increased activation of the kinase pathways, and in consequence, uncontrolled proliferation of cells. The disease predisposes to the development of both benign and malignant tumors. Malignant tumors, but not related to the nervous system occur in neurofibromatosis quite rare. The aim of the study is a literature review of NF1, with presentation of a patient with NF1 and coexisting numerous tumors: synchronous somatostatinoma and gastrointestinal stromal tumor with metachronous prostate adenocarcinoma and non-small cell lung carcinoma. And attempt to answer the question if there is a common pathway for oncogenesis of these four tumors.
Asunto(s)
Adenocarcinoma/diagnóstico por imagen , Carcinoma de Pulmón de Células no Pequeñas/diagnóstico por imagen , Neoplasias Duodenales/diagnóstico por imagen , Tumores del Estroma Gastrointestinal/diagnóstico por imagen , Neoplasias Pulmonares/diagnóstico por imagen , Neoplasias Primarias Múltiples/diagnóstico por imagen , Neurofibromatosis 1/diagnóstico por imagen , Neoplasias Pancreáticas/diagnóstico por imagen , Neoplasias de la Próstata/diagnóstico por imagen , Neoplasias Cutáneas/diagnóstico por imagen , Somatostatinoma/diagnóstico por imagen , Humanos , Masculino , Persona de Mediana Edad , Tomografía de Emisión de Positrones , Tomografía Computarizada de Emisión de Fotón ÚnicoRESUMEN
Objective: Pancreatic neuroendocrine neoplasms (PanNENs) are rare tumors arising from the endocrine pancreas; however, their prognosis differs significantly upon their proliferative state, which is characterized by histopathological grading. MiRNAs are small, noncoding RNAs posttranscriptionally regulating gene expression. Our aim was to identify miRNAs with altered expression upon proliferation which can be used as prognostic biomarkers in PanNENs. Methods: MiRNA expression profiles of 40 PanNENs were downloaded from Gene Expression Omnibus and were reanalyzed upon tumor grades (discovery cohort). Results of the reanalysis were confirmed by qRT-PCR analysis of five miRNAs on an independent validation cohort of 63 primary PanNEN samples. Cox proportional hazards survival regression models were fit for both univariate and multivariate analysis to determine the miRNAs' effect on progression-free and overall survival. Results: Nineteen miRNAs displayed differential expression between tumor grades. The altered expression of three out of five chosen miRNAs was successfully validated; hsa-miR-21, hsa-miR-10a and hsa-miR-106b were upregulated in more proliferative PanNENs compared to Grade 1 tumors. In univariate analysis, higher expression of tissue hsa-miR-21, hsa-miR-10a and hsa-miR-106b of primary PanNENs predicted worse progression-free and overall survival; however, multivariate analysis only confirmed the expression of hsa-miR-21 as an independent prognostic factor. Conclusions: The expression of hsa-miR-106b, hsa-miR-10a and especially hsa-miR-21 has prognostic relevance regarding progression-free and overall survival in patients with PanNENs.
Asunto(s)
MicroARNs/genética , Tumores Neuroendocrinos/genética , Neoplasias Pancreáticas/genética , Adulto , Anciano , Anciano de 80 o más Años , Proliferación Celular/genética , Simulación por Computador , Supervivencia sin Enfermedad , Femenino , Gastrinoma/genética , Gastrinoma/patología , Perfilación de la Expresión Génica , Humanos , Insulinoma/genética , Insulinoma/patología , Antígeno Ki-67/metabolismo , Masculino , Persona de Mediana Edad , Análisis Multivariante , Clasificación del Tumor , Tumores Neuroendocrinos/patología , Neoplasias Pancreáticas/patología , Pronóstico , Modelos de Riesgos Proporcionales , Reacción en Cadena en Tiempo Real de la Polimerasa , Reproducibilidad de los Resultados , Somatostatinoma/genética , Somatostatinoma/patología , Tasa de SupervivenciaAsunto(s)
Neoplasias Pancreáticas/diagnóstico , Pancreatitis Crónica/diagnóstico , Somatostatinoma/diagnóstico , Diagnóstico Diferencial , Humanos , Masculino , Neoplasias Pancreáticas/complicaciones , Neoplasias Pancreáticas/cirugía , Pancreaticoduodenectomía/métodos , Pancreatitis Crónica/complicaciones , Pancreatitis Crónica/cirugía , Somatostatinoma/complicaciones , Somatostatinoma/cirugía , Resultado del Tratamiento , Adulto JovenAsunto(s)
Adenocarcinoma Mucinoso , Ampolla Hepatopancreática/patología , Neurofibromatosis 1/patología , Neoplasias Pancreáticas/patología , Somatostatinoma/patología , Adenocarcinoma/diagnóstico , Adenocarcinoma/patología , Adenocarcinoma Mucinoso/diagnóstico , Adenocarcinoma Mucinoso/patología , Femenino , Humanos , Persona de Mediana Edad , Neurofibromatosis 1/diagnóstico , Neoplasias Pancreáticas/diagnóstico , Somatostatinoma/diagnósticoRESUMEN
Alrededor del 70%de los tumores endocrinos bien diferenciados asientan en el tracto gastrointestinal. Los tumores duodenales bien diferenciados constituyen solo el 2,6 % de todos los tumores neuroendocrinos (NET).El somatostatinoma es un tumor raro que se localiza en páncreas o duodeno con una incidencia de 1:40 millones.La neurofibromatosis tipo I es una enfermedad autosómica dominante, la mutación en el gen supresor de tumores NF1 favorece la aparición de neoplasias en estos pacientes.
About 70% of well-differentiated endocrine tumors arise from the gastrointestinal tract. Duodenal well-differentiated tumors account for only 2.6% of all neuroendocrine tumors. Somatostatinomas are rare neuroendocrine tumors (NETs) with an incidence of 1 in 40 million. These unusual tumors arise predominantly in the pancreas and peripancreatic duodenum. Neurofibromatosis type I is an autosomal dominant disease, the mutation in the tumor suppressor gene NF1 favors the appearance of neoplasms in these patients.